IFNG and Alzheimer disease: From a clinical perspective, it is therefore crucial to clarify whether there are certain subgroups of AD patients who would benefit from additional targeting of IFNG or, conversely, whether the inhibition of type 2 immunity alone is sufficient for the treatment of AD even in subgroups with high IFNG expression.